Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002172 · ClinicalTrials.gov registry record · NA
An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml
A NA study, sponsored by The Immune Response Corporation.
- Completed
- Registry status
- NA
- Development phase
NCT00002172: Completed NA study, sponsored by The Immune Response Corporation.
NCT00002172 is a NA study that has completed, run by The Immune Response Corporation. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002172, a NA study, has completed, sponsored by The Immune Response Corporation.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
To provide product through an expanded access program to HIV-infected patients with CD4 counts less than 300 cells/ml.
Interventions
- BIOLOGICAL HIV-1 Immunogen
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002172 record still lists
NCT00002172 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which HIV-1 Immunogen is the first listed.
NCT00002172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002172 about?
NCT00002172 is a clinical study titled "An Expanded Access Open-Label, Compassionate Use Protocol of Remune in HIV-1-Infected Adults With CD4 Count Less Than 300 Cells/Ml". To provide product through an expanded access program to HIV-infected patients with CD4 counts less than 300 cells/ml.
What is the current status of trial NCT00002172?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002172?
The interventions under investigation include: HIV-1 Immunogen (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002172?
This trial is sponsored by The Immune Response Corporation, which has 3 total clinical trials registered on ClinicalTrials.gov.